Client of a consultant lobbyist
Vertex Pharmaceuticals (Canada) Inc.
- Meetings this Parliament
- 6
- With MPs
- 4
- Since Nov 2021
- 7
- Active registrations
- 0
Most recent reported meeting: Jun 4, 2026.
Lobbying by Vertex Pharmaceuticals (Canada) Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingBills they've lobbied on
Named in their own descriptions of meetings or of their registration. Their words are quoted below each bill.
-
Bill S-201 8 mentions · latest Jun 4, 2026 In registration
“Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell…”
-
Bill S-280 44-1 (previous Parliament) 2 mentions · latest Jul 19, 2024 In registration
“Engagement with officials on Bill S-280, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell…”
Who they meet
Since the current Parliament opened.
MPs
- Juanita Nathan Liberal 1
- Tom Kmiec Conservative 1
- Salma Zahid Liberal 1
- Judy A. Sgro Liberal 1
Institutions
- House of Commons4
- Senate of Canada1
- Health Canada (HC)1
Registrations in effect
Vertex Pharmaceuticals (Canada) Inc. has no active registration. Organizations must register once paid lobbying passes the legal threshold, and their registration ends when it stops.
Reported meetings
Spreadsheet-
Reported by Stephanie Levee · Consultant
- Juanita Nathan · Member of Parliament
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Read more
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by Stephanie Levee · Consultant
- Tom Kmiec · Member of Parliament
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Read more
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by Stephanie Levee · Consultant
- Tony Ince · Senator, Senate of Canada
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Read more
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
-
Reported by Stephanie Levee · Consultant
- Salma Zahid · Member of Parliament
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework. Read more
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by Stephanie Levee · Consultant
- Judy A. Sgro · Member of Parliament
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions. Read more
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
-
Reported by Stephanie Levee · Consultant
- Justine Frame · Policy Advisor, Health Canada (HC)
Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease. Read more
Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.
Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.
Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy
Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.
Implementation of Canada's action plan for pain and federal initiatives related to pain management.
Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases
-
Reported by Stephanie Levee · Consultant
- Mohamed-Iqbal Ravalia · Senator, Senate of Canada
- Sarah Polowin · Director of Parliamentary Affairs, Senate of Canada
BudgetHealthIndustry
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.